Previously, we were showing the full history of 13D/G filings. Note: As of May 16, 2021, we no longer show owners that have not filed a 13D/G within the last year. This means that share ownership of 13D/G filings and 13F filings are oftentimes not directly comparable, so we present One value for the total shares (representing all the shares owned by the investor group), but then file a 13F reporting a different value for the total shares (representing This results in situations where an investor may file a 13D/G reporting Groups of investors (with one leading), whereas 13F filings cannot. We present 13D/G filings separately from the 13F filings because of the different treatement by the SEC. ![]() Schedule 13G indicates a passive investment of over 5%. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Redmile Group, LLC, BlackRock Inc., Vanguard Group Inc, ARKK - ARK Innovation ETF, State Street Corp, Capital World Investors, Bellevue Group AG, ARK Investment Management LLC, XBI - SPDR(R) S&P(R) Biotech ETF, and ARKG - ARK Genomic Revolution ETF.įate Therapeutics Inc (NASDAQ:FATE) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. These institutions hold a total of 131,177,142 shares. ![]() Has 518 institutional owners and shareholders that haveįiled 13D/G or 13F forms with the Securities Exchange Commission (SEC).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |